Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Journey Medical (DERM) FCF Margin (2020 - 2025)

Historic FCF Margin for Journey Medical (DERM) over the last 6 years, with Q3 2025 value amounting to 13.52%.

  • Journey Medical's FCF Margin fell 56100.0% to 13.52% in Q3 2025 from the same period last year, while for Sep 2025 it was 6.62%, marking a year-over-year increase of 416300.0%. This contributed to the annual value of 42.98% for FY2024, which is 432800.0% down from last year.
  • Latest data reveals that Journey Medical reported FCF Margin of 13.52% as of Q3 2025, which was down 56100.0% from 6.28% recorded in Q2 2025.
  • In the past 5 years, Journey Medical's FCF Margin registered a high of 54.28% during Q3 2023, and its lowest value of 108.28% during Q4 2023.
  • Moreover, its 5-year median value for FCF Margin was 18.3% (2021), whereas its average is 19.65%.
  • In the last 5 years, Journey Medical's FCF Margin tumbled by -947500bps in 2022 and then skyrocketed by 1246100bps in 2024.
  • Journey Medical's FCF Margin (Quarter) stood at 18.3% in 2021, then tumbled by -31bps to 24.03% in 2022, then crashed by -351bps to 108.28% in 2023, then surged by 115bps to 16.34% in 2024, then crashed by -183bps to 13.52% in 2025.
  • Its FCF Margin stands at 13.52% for Q3 2025, versus 6.28% for Q2 2025 and 21.55% for Q1 2025.